Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Tandem Diabetes to $25 from $40 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results that missed its targets on the top- and bottom lines. Management noted timing related issues internationally, which caused the shortfall, Piper adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNDM: